Products Affected - Description

• • Carboplatin solution for injection, Accord, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 16729-0295-12
  • Carboplatin solution for injection, Apotex, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 60505-6282-06 - discontinued
  • Carboplatin solution for injection, Apotex, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 60505-6282-07 - discontinued
  • Carboplatin solution for injection, BPI Labs, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 54288-0166-01
  • Carboplatin solution for injection, BPI Labs, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 54288-0167-01
  • Carboplatin solution for injection, Eugia US, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 55150-0386-01
  • Carboplatin solution for injection, Fresenius Kabi, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 63323-0172-60
  • Carboplatin solution for injection, Pfizer, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 61703-0339-22
  • Carboplatin solution for injection, Pfizer, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 61703-0339-50
  • Carboplatin solution for injection, Pfizer, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 61703-0339-18
  • Carboplatin solution for injection, Pfizer, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 61703-0339-56
  • Carboplatin solution for injection, Teva, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00703-4244-01

Reason for the Shortage

• • Accord did not provide a reason for the shortage. The 5 mL vials and 15 mL vials have been discontinued.
  • Apotex discontinued carboplatin in early-2026.
  • BPI did not provide a reason for the shortage.
  • Eugia has carboplatin injection on shortage due to increased demand.
  • Fresenius Kabi has carboplatin injection on shortage due to delay of shipping.
  • Ingenus has discontinued carboplatin their 45 mL and 60 mL vials.
  • Pfizer has carboplatin injection on shortage due to increased demand.
  • Teva did not provide a reason for the shortage.

Available Products

• • Carboplatin solution for injection, Accord, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 16729-0295-34
  • Carboplatin solution for injection, BPI Labs, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 54288-0165-01
  • Carboplatin solution for injection, Eugia US, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 55150-0335-01
  • Carboplatin solution for injection, Teva, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 00703-4246-01
  • Carboplatin solution for injection, Teva, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 00703-4248-01
  • Carboplatin solution for injection, Teva, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 00703-4239-01

• • Accord has carboplatin 10 mg/mL 60 mL vials on back order and the company cannot estimate a release date.
  • BPI has carboplatin 10 mg/mL 45 mL and 60 mL vials available in limited supply. The 60 mL vials are short-dated.
  • Eugia has carboplatin 10 mg/mL 60 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Fresenius Kabi has carboplatin 10 mg/mL 60 mL vials on back order and the company estimates a release date of late-April to early-May 2026.
  • Pfizer has carboplatin 10 mg/mL 5 mL and 15 mL vials available in limited supply with weekly releases. The 45 mL and 60 mL vials are on back order and the company estimates a release date of April 2026.
  • Teva has carboplatin 10 mg/mL 5 mL vials on allocation.

• • The Society of Gynecologic Oncology has a statement on conservation strategies during this shortage. This statement is available at: https://www.sgo.org/news/drugshortage/

• • Consider evaluating the health-care system's total supply of carboplatin before beginning patients on combination chemotherapy regimens containing carboplatin. If adequate supplies are not available, select an alternative regimen.
  • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for carboplatin.
  • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
  • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
  • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.